Cargando…

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration

PURPOSE: Neovascular age-related macular degeneration (nv-AMD) is the leading cause of blindness in individuals 55 years and older. The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has greatly altered the visual acuity (VA) prognosis in these patients. While many studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veluswamy, Balaji, Lee, Andy, Mirza, Rukhsana G, Gill, Manjot K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293965/ https://www.ncbi.nlm.nih.gov/pubmed/32606571 http://dx.doi.org/10.2147/OPTH.S256009

Ejemplares similares

Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration
por: Lee, Andy, et al.
Publicado: (2020)

Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration
por: Zhang, Xinyuan, et al.
Publicado: (2018)

Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
por: Phan, Long T, et al.
Publicado: (2021)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry
por: Joshi, Shrinivas, et al.
Publicado: (2023)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Flavoprotein Fluorescence Correlation with Visual Acuity Response in Patients Receiving Anti-VEGF Injection for Diabetic Macular Edema
por: Andrade Romo, Jorge S., et al.
Publicado: (2018)

Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity
por: Feigl, Beatrix, et al.
Publicado: (2007)

Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
por: Chakravarthy, Usha, et al.
Publicado: (2020)

Predictive value of pigment epithelial detachment markers for visual acuity outcomes in neovascular age-related macular degeneration
por: Shu, Yiyang, et al.
Publicado: (2023)

Functional Visual Acuity in Age-Related Macular Degeneration
por: Tomita, Yohei, et al.
Publicado: (2016)

Treatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF Agents: Predictive Factors of Long-Term Visual Outcomes
por: Pedrosa, Ana Catarina, et al.
Publicado: (2017)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Modelling Cost Effectiveness in Neovascular Age-Related Macular Degeneration: The Impact of Using Contrast Sensitivity vs. Visual Acuity
por: Butt, Thomas, et al.
Publicado: (2014)

Neovascular Age‐Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
por: Mulyukov, Zufar, et al.
Publicado: (2018)

Evaluating an automated machine learning model that predicts visual acuity outcomes in patients with neovascular age-related macular degeneration
por: Abbas, Abdallah, et al.
Publicado: (2022)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
por: Yang, Shiqi, et al.
Publicado: (2016)

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
por: Strunz, Tobias, et al.
Publicado: (2022)

Contrast Sensitivity Testing in Age-Related Macular Degeneration Using Motion Diamond Stimulus
por: Maganti, Nenita, et al.
Publicado: (2022)

Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity
por: Chang, Young Suk, et al.
Publicado: (2014)

Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline
por: Minami, Sakiko, et al.
Publicado: (2018)

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
por: Kikushima, Wataru, et al.
Publicado: (2021)

Prediction of Visual Acuity after anti-VEGF Therapy in Diabetic Macular Edema by Machine Learning
por: Zhang, Ying, et al.
Publicado: (2022)

Quantitative Autofluorescence in Non-Neovascular Age Related Macular Degeneration
por: Chandra, Shruti, et al.
Publicado: (2023)

Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration
por: Roberts, Philipp K., et al.
Publicado: (2022)

Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review
por: Wang, Patrick, et al.
Publicado: (2022)

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
por: Lu, Yan, et al.
Publicado: (2021)

Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD
por: Relton, S. D., et al.
Publicado: (2022)

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
por: Holz, Frank G, et al.
Publicado: (2016)

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
por: Arruabarrena, Carolina, et al.
Publicado: (2021)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
por: Arai, Yusuke, et al.
Publicado: (2020)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
por: Korva-Gurung, Ida, et al.
Publicado: (2023)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
por: Hirata, Akira, et al.
Publicado: (2017)

Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study
por: Staurenghi, Giovanni, et al.
Publicado: (2021)

Mental health and visual acuity in patients with age-related macular degeneration
por: Fonteh, Cheryl N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gs40vd1eg7pn123kd1uoekdbka